Background: The appropriate surgical treatment of effort thrombosis in young patients with venous thoracic outlet syndrome (TOS) is controversial. The major approaches include supraclavicular, infraclavicular, paraclavicular, and transaxillary first rib resection. We present the successful paraclavicular surgical management for the relatively rare observation of recurrent venous TOS with effort thrombosis 5 years after transaxillary rib resection.
Objective: Thoracic endovascular aortic repair (TEVAR) has expanded access to thoracic aortic aneurysm (TAA) repair, particularly for elderly and frail patients. However, there are limited data on this higher risk population to inform appropriate selection of patients. Our objective was to develop and to validate a frailty-based, procedure-specific risk score for patients undergoing TEVAR for elective TAA.
Methods: Patients undergoing nonemergent TEVAR for TAA during 2005 to 2016 in the National Surgical Quality Improvement Program database were randomized to derivation or validation cohorts. The primary outcome was 30-day major adverse events (MAEs), including mortality and major complications. Using the derivation cohort, variables associated with MAEs were identified by univariable analyses. Those with P < .05 were included in multivariable logistic regression analysis. Independent procedure-specific and frailty-related risk factors for MAEs were used to develop a pragmatic score to assess risk for TEVAR.
Results: Overall, 1920 patients were included (960 derivation, 960 validation); 16% of derivation patients had MAEs (15% major complications, 4% mortality), which were primarily associated with markers of frailty and TEVAR extent (Table) . Independent risk factors for MAEs were chronic pulmonary disease (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.3-2.6), functional dependence (OR, 2.9; 95% CI, 1.7-5.2), and zone 2 involvement (OR, 1.7; 95% CI, 1.2-2.4). Assigning each variable 1 point, a total risk score of 0 to 3 was generated with progressive rates of MAEs (Fig), enabling classification as low risk (0 points; 38% of patients; mortality <5%; MAEs <15%), intermediate risk (1 point; 45% of patients; mortality <10%; MAEs <20%), or high risk ($2 points; 17% of patients; mortality >10%; MAEs >20%). Validation patients had similar characteristics and calculated risk profile.
Conclusions: Markers of frailty and procedure extent strongly predict MAEs after TEVAR for TAA and can improve selection of patients by enabling patient-and procedure-specific risk stratification. Whereas TEVAR is safe in low-risk patients, intermediate-risk patients warrant careful discussion of the risks and benefits of aortic intervention; under certain circumstances, high-risk patients may not benefit. Further study is required to define the association between frailty and long-term outcomes. Objective: Whereas medical treatment remains the "gold standard" for acute aortic syndrome (AAS), mortality remains high. Thoracic endovascular aortic repair (TEVAR) is increasingly used for AAS, a spectrum of disease that includes complicated type B aortic dissection, penetrating aortic ulcer, and intramural hematoma (IMH). We report our institutional outcomes after TEVAR for AAS.
Methods: An Institutional Review Board-approved study of patients undergoing TEVAR for complicated AAS (ie, refractory to medical treatment, rapid aortic degeneration, malperfusion, and rupture) from 2007 through 2017 was performed. Clinical outcomes and imaging results were analyzed. Positive aortic remodeling (regression of false lumen and resolution of IMH) was assessed. Appropriate statistical analyses were performed on the data collected, and P value < .05 was considered significant.
Results: Forty patients (20 penetrating aortic ulcers, 19 complicated type B aortic dissections, 1 IMH) were identified who underwent TEVAR for AAS. The majority (22 [55%]) were female. Mean age of the patients was 62.4 years (range, 30-88 years). Mean follow-up was 13.2 months (range, 1-68 months). Most (31 [77.5%]) patients were treated in the acute phase (<14 days) of the disease. There were two (5%) immediate deaths after the procedure. The 30-day mortality was 10%. There were 14 (35%) postoperative complications, including spinal cord ischemia (2 [5%]), stroke (4 [10%]), congestive heart failure (1 [2.5%]), pneumonia (2 [5%]), and retrograde type A dissection (RTAD; 5 [12.5%] ). Development of RTAD after TEVAR was significantly associated with presence of IMH in addition to the primary AAS (P ¼ .001) and zone 3 TEVAR (P ¼ .02). Cumulative 1-year and 5-year survival after TEVAR for AAS was 77.5% and 47%. Survival was significantly reduced by postoperative complications (P ¼ .037) and negative aortic remodeling (P ¼ .003). Nine patients (22.5%) required secondary interventions after TEVAR. Twenty-eight patients (70%) demonstrated positive aortic remodeling on follow-up imaging. Need for secondary interventions was significantly associated with negative aortic remodeling (P ¼ .002).
Conclusions: TEVAR is an acceptable option for the treatment of refractory AAS. Perioperative complications, however, are not insignificant, and overall patient survival is dependent on favorable aortic remodeling. Patients with an IMH component to their AAS and having zone 3 TEVAR appear to have higher incidence of RTAD.
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